NCT06239571: R-FAM

Resilient Families Open Pilot: Dyadic Resiliency Intervention

Active, enrolled NA Last updated 28 January 2026

What this trial tests

NA trial testing Resilient Families (R-FAM) in Parents in 10 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 May 2025

Primary endpoint
1 April 2027

31 March 2028

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	8 May 2025
Primary completion	1 April 2027
Estimated completion	31 March 2028
Sites	1 location across United States

Drugs / interventions tested

• Resilient Families (R-FAM)

Conditions studied

• Parents — all drugs for Parents →

Sponsor

Massachusetts General Hospital

Who can join

18 and older, any sex, with Parents. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal is to develop, refine, and test the feasibility and acceptability of a dyadic, resiliency intervention ("Resilient Families;" R-FAM) that aims to reduce emotional distress and improve relationships among parents in the Neonatal Intensive Care Unit (NICU). To achieve this goal, my aims are three-fold: (1) develop R-FAM using stakeholder input from interviews with parent dyads and focus groups with NICU staff; (2) optimize R-FAM through an open pilot with pre/post assessments and exit interviews; and (3) test R-FAM for feasibility and acceptability through a randomized clinical trial of R-FAM compared with a minimally enhanced usual control (MEUC).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.